A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males	Anal Cancer, DNA Virus Infections, Digestive System Diseases, Digestive System Neoplasms, Disease Attributes, Genital Diseases, Infections, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin Diseases, Viral, Skin and Connective Tissue Diseases, Tumor Virus Infections, Urogenital Diseases, anogenital human papillomavirus infection, anus disorder, anus neoplasm, colorectal neoplasm, common wart, digestive system disorder, digestive system neoplasm, human papilloma virus infection, infectious disease, intestinal disorder, neoplasm, rectal disorder, rectal neoplasm, sexually transmitted disease, skin disorder, skin disorder caused by infection, viral infectious disease, viral sexually transmitted disease	Active, not recruiting	Phase 3	2025-07-31		NCT06866574

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Xiamen Innovax Biotech Co., Ltd	8
Xiamen University	16

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Fujian Provincial Center for Disease Control and Prevention	Fuzhou	China	1
Sichuan Provincial Center for Disease Control and Prevention	Chengdu	China	1
Yunnan Provincial Center for Disease Control and Prevention	Kunming	China	1
Zhejiang Provincial Center for Disease Control and Prevention	Hangzhou	China	1